Cargill Puts Bold Innovation at Center of Effort to Decarbonize Shipping
15.1.2025 08:00:00 CET | Business Wire | Press release
Continued investment in wind assisted propulsion, next-generation fuels and digital solutions key to moving the world’s goods more sustainably
Cargill is advancing a new era in sustainable shipping, putting innovation and collaboration at the core of its mission to move goods responsibly across the globe. Through wind-assisted propulsion technologies, dual-fuel methanol-powered vessels, and digital solutions, Cargill is setting the standard for helping the industry advance progress toward the International Maritime Organization’s (IMO) 2050 net-zero target. Combining technical expertise with a commitment to industry-wide partnerships, Cargill is helping to future-proof the maritime sector while enabling customers to meet their sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114753261/en/
“Decarbonizing shipping is a monumental task that requires courage, innovation, and collaboration,” said Jan Dieleman, president of Cargill’s Ocean Transportation business. “Our role extends beyond freight-shipping services; we aim to catalyze a shift across the industry toward sustainable practices. Through strategic investments in cutting-edge technology and robust partnerships, we are accelerating the journey to net-zero emissions in shipping.”
Innovating with Wind-Assisted Propulsion: The Pyxis Ocean and Beyond
Leading the charge in wind-assisted propulsion, the Pyxis Ocean—the first dry bulk vessel equipped with BAR Technologies’ WindWings®—completed its maiden voyage in 2023. WindWings are large, rigid sails that harness wind power to reduce fuel use and emissions.
In addition to WindWings, Cargill has expanded its wind-assisted technology program to include VentoFoil vertical suction sails on the NBA Magritte and rotor sails on the TR Lady. With these three vessels the company is experimenting and learning before scaling up technical, operational and commercial aspects. These technologies further utilize wind power to decrease fuel dependency and emissions, aligning with the IMO's target to have 5-10% of maritime energy from renewable sources by 2030.
Cargill believes that wind could make an important contribution to achieving decarbonization goals in the short, medium, and long term. Dieleman says that while the cost of fuels that could contribute to a zero-carbon future may remain high, developing, testing, and improving wind assisted propulsion technologies before these fuels are available could reduce reliance on them.
Transforming Fuels: Biofuels and Methanol-Powered Vessels
Alongside wind propulsion, Cargill is transforming fuel usage across its fleet. The company is pioneering biofuels made from renewable sources, such as fatty acid methyl esters (FAME), providing a drop-in fuel option to lower emissions without extensive engine modifications. In 2023, the company moved from trialing these fuels to frequent execution as it prepares to scale up. Nearly 172,000 metric tons of biofuel blends containing 63,000 metric tons of FAME was lifted in 2023. Cargill is also the first dry-bulk charterer to sign commercial agreements for dual-fuel methanol-powered ships, which are expected to be operational within the next two years. Methanol, a low-carbon alternative fuel, offers a scalable pathway to zero emissions. These methanol-powered vessels—the first of their kind in commercial service—highlight Cargill’s proactive approach in adopting sustainable fuel solutions to support both its own and its customers’ ambitious Scope 3 emissions reduction goals.
Harnessing Digital Solutions for Efficiency and Sustainability
Digital innovation is also central to Cargill ’s decarbonization efforts. Cargill is using advanced digital tools, including voyage optimization technologies, to create digital twins of its vessels. This enables optimal speed and route planning to reduce fuel consumption and emissions. Partnering with ZeroNorth, Cargill leverages these digital solutions to enhance operational efficiency and sustainability, reinforcing its commitment to data-driven progress toward net-zero.
Building a Sustainable Future Through Collaboration
Recognizing that decarbonizing the maritime industry requires a collaborative approach, Cargill partners across the sector to drive meaningful progress. As a founding member of the Maersk Mc-Kinney Moller Center for Zero Carbon Shipping, Cargill works with industry leaders to test and promote alternative fuels, including ammonia and methanol. Cargill is also a key player in the Sea Cargo Charter, a coalition dedicated to reducing shipping’s climate impact through transparency and shared decarbonization frameworks.
“As we continue this journey, we’re focused on solutions that don’t just improve our own operations but drive change across the industry,” added Dieleman. “Our vision is a shipping sector that delivers the goods the world needs while protecting our planet’s future. We’re proud to be part of this transformation and are committed to building a more sustainable future for global shipping.”
For additional information about Cargill’s efforts to decarbonize shipping, visit https://www.cargill.com/transportation/ocean-transportation-sustainability.
About Cargill
Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.
Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114753261/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom